Summary of clinical efficacy for licensed antibodies or under EUA. Bamlanivimab/Etesevimab are combination of monoclonal antibody products developed by Lilly, Casirivimab/Imdevimab by Regeneron, Tixagevimab/Cilgavimab (AZD8895/AZD1061) by AstraZeneca, BRII-196/BRII-198 by Brii Biosciences, and CT-P59 (Regdanvimab) by Celltrion. The first three combinations have been approved by the U.S. Food and Drug Administration, the fourth one by the Chinese National Medical Products Administration, and the last one by South Korea regulatory agencies.